Alejandra Marin Ruiz, MD
Internal Medicine · Dunedin, FLNPI 1891960803
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $533, 4.3 times the $124 reported in 2019.
Across 54 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$197
- Novo Nordisk$174
- AstraZeneca$141
- Exact Sciences$110
- Phathom Pharmaceuticals, Inc.$107
- Lilly USA, LLC$86
- plus $424 from 15 others
Across 4 payments — averaging $17,504 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$70K
What the payments were for
- Food & beverage$1,238100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $197 |
| Novo Nordisk | 10 | $174 |
| AstraZeneca | 2 | $141 |
| Exact Sciences | 5 | $110 |
| Phathom Pharmaceuticals, Inc. | 2 | $107 |
| Lilly USA, LLC | 5 | $86 |
| Dynavax Technologies Corporation | 3 | $63 |
| GSK | 2 | $48 |
| Pfizer | 2 | $41 |
| Novartis | 2 | $38 |
| Amgen | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Microtransponder, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Si-bone, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Merck | 1 | $16 |
| Abbott | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$124
How this compares
$1,238 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $59,929 |
| MounjaroTirzepatide | 33 | $40,935 |
| EliquisApixaban | 32 | $31,076 |
| JardianceEmpagliflozin | 19 | $19,441 |
| TrulicityDulaglutide | 18 | $16,099 |
| Atorvastatin Calcium | 168 | $1,789 |
| Losartan Potassium | 108 | $1,569 |
| Rosuvastatin Calcium | 115 | $1,540 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,248 |
| Amlodipine Besylate | 152 | $1,224 |
| Levothyroxine Sodium | 139 | $1,202 |
| SynthroidLevothyroxine Sodium | 11 | $1,112 |
| Famotidine | 55 | $1,043 |
| Omeprazole | 49 | $980 |
| Lisinopril | 98 | $833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $174 | $59,92958 claims |
| Lilly USA, LLCMounjaro, Trulicity | $86 | $57,03451 claims |
| PfizerEliquis | $41 | $31,07632 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $1,202139 claims |
| AbbVieSynthroid | $197 | $1,11211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Dunedin
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.